Akkermansia muciniphila – multifunctional bacteria
DOI:
https://doi.org/10.12775/JEHS.2023.21.01.009Keywords
gut microbiota, Akkermansia muciniphila, probiotic, dysbiosis, metabolic diseasesAbstract
Introduction: The complex symbiotic connection between the host and the gut microbiome, which has many important functions in the organism, provides an opportunity for dysbiosis to potentially serve as a catalyst for various health disorders. Akkermancia muciniphila, a bacterium that degadates mucin, is a noteworthy element of the human gut microbiome and has captured the attention of researchers due to its correlation with numerous diseases.
Aim of the study: The purpose of this research was to review literature and determine the impact of Akkermansia muciniphila in selected diseases. A systematic review was conducted using PubMed database.
State of knowledge: Studies have shown that reduced numbers of Akkermansia muciniphila have been associated with many diseases, including obesity, type 2 diabetes, atherosclerosis, fatty liver, some neurological conditions, inflammation, and response to cancer immunotherapies. Furthermore, the administration of this bacterium has been shown to have a positive impact on reducing obesity-related parameters, improving insulin sensitivity and glucose homeostasis, mitigating inflammation, and enhancing the prognosis of immune checkpoint inhibitor treatment.
Conclusions: The condition and composition of the intestinal microbiome play a significant role in the development and progression of numerous diseases. Akkermansia muciniphila, as demonstrated in various studies, is an example of a bacterium associated with beneficial effects in multiple diseases. It is regarded as a promising candidate for probiotic use.
References
Derrien M, Vaughan EE, Plugge CM, de Vos WM. Akkermansia muciniphila gen. nov., sp. nov., a human intestinal mucin-degrading bacterium. Int J Syst Evol Microbiol. 2004 Sep;54(Pt 5):1469-1476. https://doi.org/10.1099/ijs.0.02873-0
Jandhyala SM, Talukdar R, Subramanyam C, Vuyyuru H, Sasikala M, Nageshwar Reddy D. Role of the normal gut microbiota. World J Gastroenterol. 2015 Aug 7;21(29):8787-803. doi: https://doi.org/10.3748/wjg.v21.i29.8787
DAS B, Nair GB. Homeostasis and dysbiosis of the gut microbiome in health and disease. J Biosci. 2019 Oct;44(5):117. doi: https://doi.org/10.1007/s12038-019-9926-y
de Vos WM. Microbe Profile: Akkermansia muciniphila: a conserved intestinal symbiont that acts as the gatekeeper of our mucosa. Microbiology (Reading). 2017 May;163(5):646-648. https://doi.org/10.1099/mic.0.000444
Ruas-Madiedo P, Gueimonde M, Fernández-García M, de los Reyes-Gavilán CG, Margolles A. Mucin degradation by Bifidobacterium strains isolated from the human intestinal microbiota. Appl Environ Microbiol. 2008 Mar;74(6):1936-40. https://doi.org/10.1128/AEM.02509-07
Derrien M, Collado MC, Ben-Amor K, Salminen S, de Vos WM. The Mucin degrader Akkermansia muciniphila is an abundant resident of the human intestinal tract. Appl Environ Microbiol. 2008 Mar;74(5):1646-8. https://doi.org/10.1128/AEM.01226-07
Iwaza R, Wasfy RM, Dubourg G, Raoult D and Lagier J-C (2022) Akkermansia muciniphila: The state of the art, 18 years after its first discovery. Front. Gastroenterol. 1:1024393. doi: https://doi.org/10.3389/fgstr.2022.1024393
Malik VS, Willett WC, Hu FB. Global obesity: trends, risk factors and policy implications. Nat Rev Endocrinol. 2013 Jan;9(1):13-27. https://doi.org/10.1038/nrendo.2012.199
Björntorp P. The associations between obesity, adipose tissue distribution and disease. Acta Med Scand Suppl. 1988;723:121-34. https://doi.org/10.1111/j.0954-6820.1987.tb05935.x
Sonnenburg JL, Bäckhed F. Diet-microbiota interactions as moderators of human metabolism. Nature. 2016 Jul 7;535(7610):56-64. https://doi.org/10.1038/nature18846
Depommier C, Van Hul M, Everard A, Delzenne NM, De Vos WM, Cani PD. Pasteurized Akkermansia muciniphila increases whole-body energy expenditure and fecal energy excretion in diet-induced obese mice. Gut Microbes. 2020 Sep 2;11(5):1231-1245. https://doi.org/10.1080/19490976.2020.1737307
Wu F, Guo X, Zhang M, Ou Z, Wu D, Deng L et al. An Akkermansia muciniphila subtype alleviates high-fat diet-induced metabolic disorders and inhibits the neurodegenerative process in mice. Anaerobe. 2020 Feb;61:102138. https://doi.org/10.1016/j.anaerobe.2019.102138
Yang M, Bose S, Lim S, Seo J, Shin J, Lee D et al. Beneficial Effects of Newly Isolated Akkermansia muciniphila Strains from the Human Gut on Obesity and Metabolic Dysregulation. Microorganisms. 2020 Sep 14;8(9):1413. https://doi.org/10.3390/microorganisms8091413
Depommier C, Everard A, Druart C, Plovier H, Van Hul M, Vieira-Silva S et al. Supplementation with Akkermansia muciniphila in overweight and obese human volunteers: a proof-of-concept exploratory study. Nat Med. 2019 Jul;25(7):1096-1103. https://doi.org/10.1038/s41591-019-0495-2
Kumar, Vinay; Faust, Nelson; Abbas, Abul K.; Cotran, Ramzi S.; Robbins, Stanley L.: Robbins and Cotran Pathologic Basis of Disease. ed. 7th. Philadelphia, Pa.: Saunders, 2005, pp. 1194–1195. ISBN 0-7216-0187-1. (eng.)
Gurung M, Li Z, You H, Rodrigues R, Jump DB, Morgun A et al. Role of gut microbiota in type 2 diabetes pathophysiology. EBioMedicine. 2020 Jan;51:102590. https://doi.org/10.1016/j.ebiom.2019.11.051
Everard A, Belzer C, Geurts L, Ouwerkerk JP, Druart C, Bindels LB et al. Cross-talk between Akkermansia muciniphila and intestinal epithelium controls diet-induced obesity. Proc Natl Acad Sci U S A. 2013 May 28;110(22):9066-71. https://doi.org/10.1073/pnas.1219451110
Perraudeau F, McMurdie P, Bullard J, Cheng A, Cutcliffe C, Deo A et al. Improvements to postprandial glucose control in subjects with type 2 diabetes: a multicenter, double blind, randomized placebo-controlled trial of a novel probiotic formulation. BMJ Open Diabetes Res Care. 2020 Jul;8(1):e001319. https://doi.org/10.1136/bmjdrc-2020-001319
Wu H, Esteve E, Tremaroli V, Khan MT, Caesar R, Mannerås-Holm L et al. Metformin alters the gut microbiome of individuals with treatment-naive type 2 diabetes, contributing to the therapeutic effects of the drug. Nat Med. 2017 Jul;23(7):850-858. https://doi.org/10.1038/nm.4345
de la Cuesta-Zuluaga J, Mueller NT, Corrales-Agudelo V, Velásquez-Mejía EP, Carmona JA, Abad JM et al. Metformin Is Associated With Higher Relative Abundance of Mucin-Degrading Akkermansia muciniphila and Several Short-Chain Fatty Acid-Producing Microbiota in the Gut. Diabetes Care. 2017 Jan;40(1):54-62. https://doi.org/10.2337/dc16-1324
Shin NR, Lee JC, Lee HY, Kim MS, Whon TW, Lee MS et al. An increase in the Akkermansia spp. population induced by metformin treatment improves glucose homeostasis in diet-induced obese mice. Gut. 2014 May;63(5):727-35. https://doi.org/10.1136/gutjnl-2012-303839
Mozaffarian D, Benjamin EJ, Go AS, Arnett DK, Blaha MJ, Cushman M et al.; American Heart Association Statistics Committee; Stroke Statistics Subcommittee. Heart Disease and Stroke Statistics-2016 Update: A Report From the American Heart Association. Circulation. 2016 Jan 26;133(4):e38-360. https://doi.org/10.1161/CIR.0000000000000350
Tang WH, Kitai T, Hazen SL. Gut Microbiota in Cardiovascular Health and Disease. Circ Res. 2017 Mar 31;120(7):1183-1196. https://doi.org/10.1161/CIRCRESAHA.117.309715
Peng J, Xiao X, Hu M, Zhang X. Interaction between gut microbiome and cardiovascular disease. Life Sci. 2018 Dec 1;214:153-157. https://doi.org/10.1016/j.lfs.2018.10.063
Li J, Lin S, Vanhoutte PM, Woo CW, Xu A. Akkermansia Muciniphila Protects Against Atherosclerosis by Preventing Metabolic Endotoxemia-Induced Inflammation in Apoe-/- Mice. Circulation. 2016 Jun 14;133(24):2434-46. https://doi.org/10.1161/CIRCULATIONAHA.115.019645
He X, Bai Y, Zhou H, Wu K. Akkermansia muciniphila Alters Gut Microbiota and Immune System to Improve Cardiovascular Diseases in Murine Model. Front Microbiol. 2022 Jun 14;13:906920. https://doi.org/10.3389/fmicb.2022.906920
Bashiardes S, Shapiro H, Rozin S, Shibolet O, Elinav E. Non-alcoholic fatty liver and the gut microbiota. Mol Metab. 2016 Jun 14;5(9):782-94. https://doi.org/10.1016/j.molmet.2016.06.003
Abu-Shanab A, Quigley EM. The role of the gut microbiota in nonalcoholic fatty liver disease. Nat Rev Gastroenterol Hepatol. 2010 Dec;7(12):691-701. https://doi.org/10.1038/nrgastro.2010.172
Le Roy T, Llopis M, Lepage P, Bruneau A, Rabot S, Bevilacqua C et al. Intestinal microbiota determines development of non-alcoholic fatty liver disease in mice. Gut. 2013 Dec;62(12):1787-94. https://doi.org/10.1136/gutjnl-2012-303816
Kim S, Lee Y, Kim Y, Seo Y, Lee H, Ha J et al. Akkermansia muciniphila Prevents Fatty Liver Disease, Decreases Serum Triglycerides, and Maintains Gut Homeostasis. Appl Environ Microbiol. 2020 Mar 18;86(7):e03004-19. https://doi.org/10.1128/AEM.03004-19
Schnabl B, Brenner DA. Interactions between the intestinal microbiome and liver diseases. Gastroenterology. 2014 May;146(6):1513-24. https://doi.org/10.1053/j.gastro.2014.01.020
Derrien M, Van Baarlen P, Hooiveld G, Norin E, Müller M, de Vos WM. Modulation of Mucosal Immune Response, Tolerance, and Proliferation in Mice Colonized by the Mucin-Degrader Akkermansia muciniphila. Front Microbiol. 2011 Aug 1;2:166. https://doi.org/10.3389/fmicb.2011.00166
Png CW, Lindén SK, Gilshenan KS, Zoetendal EG, McSweeney CS, Sly LI et al. Mucolytic bacteria with increased prevalence in IBD mucosa augment in vitro utilization of mucin by other bacteria. Am J Gastroenterol. 2010 Nov;105(11):2420-8. https://doi.org/10.1038/ajg.2010.281
Earley H, Lennon G, Balfe Á, Coffey JC, Winter DC, O'Connell PR. The abundance of Akkermansia muciniphila and its relationship with sulphated colonic mucins in health and ulcerative colitis. Sci Rep. 2019 Oct 30;9(1):15683. https://doi.org/10.1038/s41598-019-51878-3
Al Omran Y, Aziz Q. The brain-gut axis in health and disease. Adv Exp Med Biol. 2014;817:135-53. https://doi.org/10.1007/978-1-4939-0897-4_6
Chen T, Wang R, Duan Z, Yuan X, Ding Y, Feng Z et al. Akkermansia muciniphila Protects Against Psychological Disorder-Induced Gut Microbiota-Mediated Colonic Mucosal Barrier Damage and Aggravation of Colitis. Front Cell Infect Microbiol. 2021 Oct 14;11:723856. https://doi.org/10.3389/fcimb.2021.723856
Xu M, Xu X, Li J, Li F. Association Between Gut Microbiota and Autism Spectrum Disorder: A Systematic Review and Meta-Analysis. Front Psychiatry. 2019 Jul 17;10:473. https://doi.org/10.3389/fpsyt.2019.00473
Blacher E, Bashiardes S, Shapiro H, Rothschild D, Mor U, Dori-Bachash M et al. Potential roles of gut microbiome and metabolites in modulating ALS in mice. Nature. 2019 Aug;572(7770):474-480. https://doi.org/10.1038/s41586-019-1443-5
Cattaneo A, Cattane N, Galluzzi S, Provasi S, Lopizzo N, Festari C et al. Association of brain amyloidosis with pro-inflammatory gut bacterial taxa and peripheral inflammation markers in cognitively impaired elderly. Neurobiol Aging. 2017 Jan;49:60-68. https://doi.org/10.1016/j.neurobiolaging.2016.08.019
Harach T, Marungruang N, Duthilleul N, Cheatham V, Mc Coy D K, Neher J J et al. Reduction of Abeta amyloid pathology in APPPS1 transgenic mice in the absence of gut microbiota. Sci Rep 7, 41802 (2017). https://doi.org/10.1038/srep41802
Ou Z, Deng L, Lu Z, Wu F, Liu W, Huang D et al. Protective effects of Akkermansia muciniphila on cognitive deficits and amyloid pathology in a mouse model of Alzheimer's disease. Nutr Diabetes. 2020 Apr 22;10(1):12. https://doi.org/10.1038/s41387-020-0115-8
Tsilimigras MC, Fodor A, Jobin C. Carcinogenesis and therapeutics: the microbiota perspective. Nat Microbiol. 2017 Feb 22;2:17008. https://doi.org/10.1038/nmicrobiol.2017.8
Derosa L, Routy B, Thomas A M, Iebba V, Zalcman G, Friard S et al. Intestinal Akkermansia muciniphila predicts clinical response to PD-1 blockade in patients with advanced non-small-cell lung cancer. Nat Med 28, 315–324 (2022). https://doi.org/10.1038/s41591-021-01655-5
Routy B, Le Chatelier E, Derosa L, Duong CPM, Alou MT, Daillère R et al. Gut microbiome influences efficacy of PD-1-based immunotherapy against epithelial tumors. Science. 2018 Jan 5;359(6371):91-97. https://doi.org/10.1126/science.aan3706
Downloads
Published
How to Cite
Issue
Section
License
Copyright (c) 2023 Alicja Wosińska, Dorota Pazik, Inga Łopuszyńska, Katarzyna Kosecka, Patryk Rudziński, Aleksandra Cieślik, Anna Jargieło, Karolina Kosieradzka, Dominik Adamowicz, Justyna Stańczyk
This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.
The periodical offers access to content in the Open Access system under the Creative Commons Attribution-NonCommercial-ShareAlike 4.0
Stats
Number of views and downloads: 534
Number of citations: 0
